

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Flipped C-Terminal Ends of APOA1 Promote ABCA1-dependent Cholesterol Efflux by Small HDLs

Yi He, PhD¹, Chiara Pavanello, PhD², Patrick M. Hutchins, PhD¹, Chongren Tang, PhD¹, Mohsen Pourmousa, PhD³, Tomas Vaisar, PhD¹, Hyun D. Song, PhD⁴, Richard W. Pastor, PhD³, Alan T. Remaley, MD, PhD⁵, Ira J. Goldberg, MD⁶, Tina Costacou, PhD⁷, W. Sean Davidson, PhD⁸, Karin E. Bornfeldt, PhD¹, Laura Calabresi, PhD², Jere P. Segrest, MD⁴, and Jay W. Heinecke, MD¹

¹Department of Medicine, University of Washington, Seattle, WA, 98109, USA; ²Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy; ³Laboratory of Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892; ⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37240, USA; ⁵Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD 20892; ⁶Department of Medicine, New York University, New York, NY, 10016, USA; ⁷Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 15261, USA; ⁸Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45237, USA

Correspondence: Jay Heinecke, 850 Republican St, Box 358055, UW Medicine, Seattle, WA 98109 USA. E-mail: heinecke@uw.edu

Keywords: ABCA1, molecular dynamics simulation, cholesterol efflux capacity, chemical crosslinking, peptide analysis

Abbreviations and acronyms: ABCA1, ATP-binding cassette transporter A1; APOA1, apolipoprotein A1; APOB, apolipoprotein B; BHK, baby hamster kidney; calibrated IMA, calibrated ion mobility analysis; CEC, cholesterol efflux capacity; CVD, cardiovascular disease; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; HDL-C, high-density lipoprotein cholesterol; HDL-P, HDL particle concentration determined by calibrated IMA; LCAT, lecithin-cholesterol acyltransferase; LDL-C, low-density lipoprotein cholesterol; L-HDL, large HDL; M-HDL, medium HDL; MS, mass spectrometry; r-HDL, reconstituted HDL; S-HDL, small HDL; XS-HDL, extra small HDL; MD, molecular dynamics.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69

Abstract

Background: Cholesterol efflux capacity (CEC) predicts cardiovascular disease (CVD) independently of HDL cholesterol (HDL-C) levels. Isolated small HDL particles are potent promoters of macrophage CEC by the ABCA1 pathway, but the underlying mechanisms are unclear.

Methods: We used model system studies of reconstituted HDL and plasma from control and lecithin-cholesterol acyltransferase (LCAT)-deficient subjects to investigate the relationships among the sizes of HDL particles, the structure of APOA1 in the different particles, and the CECs of plasma and isolated HDLs.

Results: We quantified macrophage and ABCA1 CEC of four distinct sizes of reconstituted HDL (r-HDL). CEC increased as particle size decreased. MS/MS analysis of chemically crosslinked peptides and molecular dynamics simulations of APOA1 (HDL's major protein) indicated that the mobility of that protein's C-terminus was markedly higher and flipped off the surface in the smallest particles. To explore the physiological relevance of the model system studies, we isolated HDL from LCAT-deficient subjects, whose small HDLs—like r-HDLs—are discoidal and composed of APOA1, cholesterol, and phospholipid. Despite their very low plasma levels of HDL particles, these subjects had normal CEC. In both the LCAT-deficient subjects and control subjects, the CEC of isolated extra-small HDL (a mixture of extra-small and small HDL by calibrated ion mobility analysis) was 3–5-fold greater than that of the larger sizes of isolated HDL. Incubating LCAT-deficient plasma and control plasma with human LCAT converted extra-small and small HDL particles into larger particles, and it markedly inhibited CEC.

Conclusions: We present a mechanism for the enhanced CEC of small HDLs. In smaller particles, the C-termini of the two antiparallel molecules of APOA1 are flipped off the lipid surface of HDL. This extended conformation allows them to engage with ABCA1. In contrast, the C-termini of larger HDLs are unable to interact productively with ABCA1 because they form a helical bundle that strongly adheres to the lipid on the particle. Enhanced CEC, as seen with the smaller particles, predicts decreased CVD risk. Thus, extra-small and small HDLs may be key mediators and indicators of HDL's cardioprotective effects.

70

Clinical Perspective (100 words)

- 71 • Using chemical crosslinking and molecular dynamics simulations, we showed that
72 the C-termini of APOA1, HDL's major protein, have increased mobility and
73 conformational freedom in small HDL particles.
- 74 • The enhanced mobility of the C-termini of APOA1 in small HDLs allows the C-termini
75 to 'flip' off a particle's surface, activating ABCA1 thereby stimulating cholesterol
76 removal from cells.
- 77 • Because of small HDLs' vital role in cholesterol efflux, quantification of HDL-P (the
78 size and concentration of HDL subspecies) might be a better metric for gauging
79 cardiovascular disease risk than HDL-cholesterol levels.
- 80 • Therapeutic interventions that increase small HDL levels, with or without increasing
81 HDL-cholesterol levels, may be cardioprotective.

82

Introduction

83 The risk of cardiovascular disease (CVD) strongly and inversely associates with plasma
84 levels of high-density lipoprotein cholesterol (HDL-C).¹ However, pharmacological
85 interventions that elevate HDL-C have failed to lower CVD risk in statin-treated subjects,
86 suggesting that the association between HDL-C and CVD risk is indirect.² It is therefore
87 critical to identify new mechanisms that inversely link HDL to CVD risk and do not
88 involve HDL-C.^{3,4}

89 One proposed cardioprotective function of HDL is promotion of cholesterol efflux from
90 lipid-laden macrophages, which play critical roles in all stages of atherogenesis.⁵ Two
91 early steps in this pathway involve ATP-binding cassette transporters—ABCA1 and
92 ABCG1. Initially, ABCA1 mediates cholesterol efflux from macrophages to lipid-poor
93 apolipoproteins⁶ and small dense HDL.^{7,8} Lecithin-cholesterol acyltransferase (LCAT)
94 then promotes HDL maturation by catalyzing the conversion of free cholesterol to
95 cholesteryl esters, which are then transferred from the surface to the core, generating
96 larger HDL particles.⁹ ABCG1 exports cellular cholesterol to larger HDL particles that
97 deliver cholesterol to the liver for excretion in bile.²

98 Rothblat, Rader, and colleagues demonstrated that serum HDL (serum depleted of
99 lipoproteins that contain apolipoprotein B [APOB]) promotes cholesterol efflux from
100 cultured macrophages, thus mimicking the key early steps in reverse cholesterol
101 transport from macrophages.^{10,11} The magnitude of cholesterol efflux to serum HDL,
102 termed cholesterol efflux capacity (CEC), is largely independent of HDL-C.^{10,11}
103 However, large clinical studies demonstrate that macrophage CEC and ABCA1-specific
104 CEC of serum HDL strongly and negatively associate with prevalent and incident
105 CVD.¹² Importantly, CEC predicts CVD independently of HDL-C.¹¹⁻¹³ These results
106 suggest that CEC is a critical contributor to HDL's proposed anti-atherogenic functions
107 in humans.

108 Lecithin-cholesterol acyltransferase (LCAT) is widely regarded as an important driving
109 force for mobilizing cholesterol from tissues to the liver for excretion. However, subjects
110 with complete LCAT deficiency do not appear to be at increased risk for CVD¹⁴ despite
111 having very low HDL-C levels. Animal models of atherosclerosis have yielded conflicting
112 results on the impact of LCAT deficiency and overexpression.^{15,16} Serum from LCAT-
113 deficient subjects exhibits elevated ABCA1-dependent cellular cholesterol efflux even
114 though efflux via ABCG1 and SR-B1 is impaired, suggesting that cholesterol efflux by
115 the ABCA1 pathway might explain why those subjects are not at high risk for CVD.¹⁷

116 CSL-112, a reconstituted HDL particle composed of human APOA1 and
117 phosphatidylcholine, was designed to mimic small HDLs.¹⁸ The drug, which markedly
118 enhances the ABCA1 CEC of human plasma, promotes the remodeling of HDL resulting
119 in higher levels of small and lipid-poor APOA1 particles.¹⁹

120 Small HDLs account for most of serum HDL's CEC activity.^{7,8} However, the underlying
121 mechanisms are poorly understood. To explore potential mechanisms, we combined
122 functional and structural studies of reconstituted HDL particles (r-HDL) with studies of
123 control and LCAT-deficient subjects. Our studies reveal that the C-terminus of APOA1
124 in smaller HDLs becomes available to engage ABCA1, the first key step in cholesterol
125 export from cells.

126

127

128

Experimental Methods

129 **Generation of reconstituted HDL (r-HDL) particles.** Discoidal r-HDL was prepared
130 from recombinant human APOA1, 1-palmitoyl-oleoyl-phosphatidylcholine (POPC), and
131 free cholesterol by cholate dialysis.²⁰⁻²² The composition of the different size of particles
132 are (APOA1:free cholesterol:POPC, mol/mol): r-HDL-80, 1.0:1.8:34; r-HDL-88,
133 1.0:2.9:52.7; r-HDL-96, 1.0:4.7:90.6; r-HDL-120, 1.0:4.7:140.²²

134 **Calibrated ion mobility analysis (IMA).** The sizes of r-HDL and human HDL particles
135 were quantified with a scanning mobility particle sizer spectrometer (TSI Inc.,
136 Shoreview, MN, model 3080N).²³⁻²⁵ The concentrations of r-HDL and HDL particles
137 (mol/L) were determined using a calibration curve of glucose oxidase.²³

138
139 **Chemical crosslinking of r-HDL.** Reconstituted HDLs (r-HDLs) were crosslinked with
140 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) in phosphate-
141 buffered saline (pH 6.5),^{20,26} and further fractionated by high-resolution size exclusion
142 chromatography to isolate monomeric HDL particles. Details are provided in
143 Supplemental Material.

144 **Proteolytic digestion and mass spectrometry analysis.** Details are provided in
145 Supplemental Material.

146 **Molecular dynamics simulations of r-HDL.** Molecular dynamics (MD) trajectories of r-
147 HDL-80 and r-HDL-90 were calculated using a combination of all-atom simulation,
148 simulated tempering, and coarse-grained (CG) methods (Supplemental Material).²⁷⁻³⁰
149 Simulations of r-HDL-100 and r-HDL-120 (termed r-HDL-110) were reported
150 previously.²⁷ Because different preparations of the largest r-HDL particles range in size
151 from 110–120 Å,²² we term these r-HDL-120 to be consistent with the size of the largest
152 particles used here.

153 **HDL contact map analyses.** Inter- and intramolecular contact maps between C α atoms
154 used a cutoff distance of 15.1 Å.²⁷ A total of 2,084 and 1,042 frames from the last half of
155 20 μ s and 10 μ s simulations were used for the r-HDL-100 and r-HDL-120 particles,
156 respectively.²⁷ A total of 100 frames extracted from the last half of 200 μ s CG
157 simulations of r-HDL-80 and r-HDL-90 particles were converted to all-atom structures to
158 develop the contact maps. Contact maps were plotted using Gnuplot version 5.2
159 (<http://gnuplot.info>).

160 **Cholesterol efflux capacity (CEC).** Macrophage cholesterol efflux capacity was
161 assessed with J774 macrophages labeled with [³H]cholesterol and stimulated with a
162 cAMP analog.¹⁰ Efflux via the ABCA1 pathway was measured with baby hamster kidney
163 (BHK) cells that expressed mifepristone-inducible human ABCA1 and were labeled with
164 [³H]cholesterol.⁶

165 **LCAT-deficient and control subjects.** Twenty-four subjects; 4 carriers of two mutant
166 LCAT alleles (termed LCAT^{-/-} subjects), 6 carriers of 1 mutant LCAT allele (LCAT^{+/-}),
167 and 14 non-carriers (LCAT^{+/+}) were from an Italian family study. The Italian LCAT
168 deficient cohort includes related carriers (**Supplemental Table S1**). The study was

169 approved by the institutional ethical committee.³¹ All subjects gave informed consent.
170 Aliquots of serum from subjects who had fasted overnight were immediately frozen and
171 stored at -80°C until analysis. Serum lipid levels and LCAT activity of the Italian cohort
172 were determined as described.³¹

173 **Incubation of control and LCAT-deficient plasma with LCAT.** Details are provided in
174 Supplemental Material.³²

175 **HDL Isolation.** For functional studies, HDL was first isolated by ultracentrifugation
176 (density 1.063–1.210 g/mL)³³ from serum of control subjects (n=4) and LCAT^{-/-} subjects
177 (n=5) and then fractionated on a Superdex 200 Increase 10/300 GL column. Details are
178 provided in Supplemental Material.

179 **Data availability.** All data supporting the findings of this study are available in the
180 article and/or its supplemental materials.

181 **Statistical Analyses.** Statistical analyses were performed with STATA software version
182 12 (Stata Corp, College Park, TX) and with SAS v.9.4 (SAS Inc, Cary, NC, USA). Mixed
183 effect models, considering family as a random effect, with Tukey-Kramer post-hoc tests
184 were used to compare the means of three or more groups. One-way ANOVA was used
185 to analyze laboratory experiments. Linear regression was used to investigate the
186 correlation of serum HDL CEC with HDL particle concentration for each subspecies.
187 Parametric or non-parametric analyses were based on the Shapiro-Wilk test for
188 normality. The ratio t-test (GraphPad) was used for the analysis of plasma incubations
189 with/without LCAT. The null hypothesis is that the average of the logarithms of the ratio
190 of each pair is zero. *P*-values <0.05 were considered significant. Unless otherwise
191 stated, values represent means \pm standard deviations.

192 Results

193 Reconstituted small HDL particles promote macrophage CEC and ABCA1 CEC as 194 effectively as lipid-free APOA1.

195 We used reconstituted discoidal HDL (r-HDL) as a model system to investigate how
196 particle size affects HDL's ability to promote CEC.^{20,22} To quantify cholesterol efflux by
197 macrophages and the ABCA1 pathway, we used validated model systems.^{8,10,11} r-HDLs
198 were fractionated into 4 different sizes of particles, using high-resolution size exclusion
199 chromatography.²⁰ We term these particles r-HDL-80, r-HDL-88, r-HDL-96, and r-HDL-
200 120 because their diameters are respectively 80 Å, 88 Å, 96 Å, and 110-120 Å as
201 determined by calibrated IMA (**Fig. 1A**). These values are in excellent agreement with
202 those previously determined by non-denaturing gradient gel electrophoresis and by
203 quantification of the hydrodynamic Stokes' diameters of the particles.²²

204 Each particle population exhibited a symmetrical Gaussian-like distribution and was
205 clearly distinguishable from the other sizes of particles by IMA (**Fig. 1A**). The r-HDL
206 particles were similar in size to human XS-HDL, S-HDL, M-HDL, and L-HDL (see
207 below).

208 At equimolar concentrations, the smallest r-HDL-80 particles were as effective as lipid-
209 free APOA1 at promoting both macrophage CEC and ABCA1 CEC (**Fig. 1B**). The r-
210 HDL-88 particles were less effective, and the two largest r-HDL particles (r-HDL-96 and
211 r-HDL-120) failed to promote either macrophage CEC or ABCA1 CEC.

212 **Probing the structure of APOA1 in r-HDLs with MS/MS**

213 In their double belt model for HDL, Segrest et al.³⁴ proposed that 2 molecules of APOA1
214 form an anti-parallel helical bundle that encircles the edge of the discoidal HDL particle.
215 The crystal structure of N-terminally truncated APOA1³⁵ and chemical crosslinking
216 studies of r-HDL^{20,27,36} and human HDL²⁰ support this model.

217 In contrast to APOA1's central region, which forms a stable helical bundle, the N- and
218 C-terminal regions of APOA1 in HDL are more flexible and capable of assuming a
219 variety of conformations.^{22,27,36,37} These regions of the protein are also important for
220 promoting ABCA1-dependent cholesterol efflux.³⁶ To investigate the structures of the
221 different regions of APOA1 in the different sizes of r-HDL, we used EDC (1-ethyl-3-(3-
222 dimethylaminopropyl)carbodiimide hydrochloride)²⁰ to generate intramolecular and
223 intermolecular zero-order crosslinks in APOA1. EDC reacts with the amino group of
224 lysine residues that are close to the carboxylic acid group of aspartate and glutamate to
225 form an amide bond. Thus, EDC crosslinks identify salt bridges in structures. The
226 crosslinked r-HDLs were reisolated by high-resolution size exclusion chromatography to
227 eliminate HDL particles that were crosslinked to each other. Importantly, all crosslinking
228 reactions were carried out at low concentrations of EDC in phosphate-buffered normal
229 saline at pH 6.5, which more closely mimics physiological conditions than those used to
230 crystallize proteins.

231 After the crosslinked APOA1 was digested, the resulting peptide mixture was
232 fractionated by capillary liquid chromatography and analyzed by tandem MS/MS. To
233 distinguish between inter- and intramolecular crosslinks of APOA1 in r-HDL, we used a
234 1:1 mixture of human [¹⁴N]APOA1 (light, L) and [¹⁵N]APOA1 (heavy, H) (isotopic
235 purity >99%) to generate the particles.^{20,38} Three combinations of crosslinks are
236 possible: L-L, L-H, and H-H. The L and H forms of APOA1 are chemically identical but
237 differ in molecular mass, making intramolecular and intermolecular crosslinks readily
238 distinguishable in MS1 scans. For intra-protein crosslinks, where the protein is linked to
239 itself, only L-L and H-H forms are detected (relative abundance ~1:1). For inter-protein
240 crosslinks, LL, L-H, and H-H peptides are detected (relative abundance ~1:2:1)
241 (**Supplemental Material, Fig. S1 and S2**).^{20,38}

242 **Different sizes of r-HDL exhibit distinct patterns of intramolecular and** 243 **intermolecular crosslinks between peptides in the N-terminal and C-terminal** 244 **regions of APOA1.**

245 This approach identified 34 intramolecular and 31 intermolecular crosslinks in the four
246 sizes of r-HDL (**Supplemental Material, Table S2**). Similar numbers of intramolecular
247 crosslinks were detected in the three largest particles (r-HDL-120, 8 crosslinks; r-HDL-
248 96, 6 crosslinks; r-HDL-88, 7 crosslinks). In contrast, we identified twice as many
249 intramolecular crosslinks in the r-HDL-80 particle (13 crosslinks). These observations
250 indicate that APOA1 has greater conformational freedom in the smallest r-HDL particles
251 than in the other sizes of HDL.

252 **Probing the behavior of HDL particles over time with molecular dynamic** 253 **simulations**

254 To investigate how APOA1 conformation and mobility vary in the different sizes of r-
255 HDL, we used a computational method called molecular dynamics (MD). Here

256 trajectories of systems modeling r-HDL (2 APOA1 bound to a nanodisc composed of
257 POPC and ~10% cholesterol, and surrounded by water) are generated for multiple
258 microseconds. The result is a series of snapshots of the dynamic evolution for all of the
259 atoms in the system.

260 We previously used this approach to generate trajectories of r-HDL-100 and r-HDL-120
261 particles (100 Å and 120 Å diameter particles, Supplemental Material).²⁷ To generate
262 the double belt models for r-HDL-80 and r-HDL-90 particles (80 Å and 90 Å diameter
263 particles), we ran MD simulations after removing cholesterol and POPC from the
264 computer generated r-HDL-100 particle (Supplemental Material). We then determined
265 whether the crosslinks we identified in APOA1 in the different sizes of r-HDL were
266 consistent with the double belt model.³⁴

267 To perform this analysis, we compared inter- and intramolecular distances between C α
268 atoms in the models, using an HDL contact map to plot a detected peptide by the
269 position of its two amino acids in APOA1's sequence. The maximum distance between
270 the backbone C α atoms of amino acids in the crosslinked peptides is the sum of the
271 length of two side chains plus the length of the amide bond formed by EDC (10.5 Å for
272 K–D linkage and 12.1 Å for K–E). **Fig. 2** shows the position of each crosslink in the
273 contact maps for the simulated belt structure for each size of HDL. The cutoff radius for
274 the crosslink residing in the double belt model was 15.1 Å (12.1 Å for the K–D crosslink
275 plus a 3 Å motion averaging factor).²⁷

276 Only one of the crosslinks detected in the largest particle (r-HDL-120) was inconsistent
277 with the double belt model of HDL (**Fig. 2A**; intermolecular crosslinks, red regions;
278 intramolecular crosslinks, green regions). Just two of the crosslinks in the r-HDL-100
279 particle were inconsistent (**Fig. 2B**). In contrast, 7 and 9 crosslinks in the r-HDL-90 and
280 r-HDL-80 particles were inconsistent with the prototypical double belt model. In r-HDL-
281 90, four of the 7 crosslinks were in the C-terminus of APOA1; in r-HDL-80, six of the 9
282 crosslinks were in the C-terminus (**Fig. 2C-D**). The large number of crosslinks in the C-
283 terminus of the two smallest particles (r-HDL-90 and r-HDL-80) indicates that this region
284 is more loosely organized than in the larger particles and thus underwent a larger
285 number of cross-linking reactions in the experiment.

286 These observations indicate that the central region of the APOA1 dimer is organized as
287 a double belt in all the sizes of r-HDL we studied. In contrast, the N-terminal and C-
288 terminal regions differ according to particle size. Specifically, the C-termini of APOA1
289 are markedly more mobile in the two smallest particles. Many of the observed crosslinks
290 in the N-termini of APOA1 of the three smallest HDLs also fell outside the contact zones
291 predicted by the double belt model (**Fig. 2B-D**), which is consistent with the proposal
292 that the N-terminus APOA1 in r-HDL-100 is hinged.²⁷

293 **The C-termini of small HDL particles exhibit greater mobility than those of large** 294 **HDL particles.**

295 **Figure 3A-H** illustrates the conformational states of APOA1 obtained by MD simulations
296 of the HDL particles of varying sizes, with lipids and water excluded from the image for
297 clarity. In the case of r-HDL-120 particles, the two proteins adopt a predominantly
298 double-belt arrangement, although some displacement of the C-terminal helices (H10A
299 and B) occurs.²⁷ Disorder in the N-terminal region (residues 1-43) is noticeable in r-

300 HDL-100 particles, and both the N- and C-termini lose their double-belt characteristics
301 in r-HDL-90 particles. Both C-termini are flipped off the lipid edge in the r-HDL-90
302 particles (**Fig. 3E,F**).

303 The structure of the smallest particle, r-HDL-80, markedly differs from that of the larger
304 r-HDL particles. The smallest particles are shaped like a spherical micelle, deviating
305 from the disk-like structure, and the double-belt arrangement is largely absent except for
306 helix 5 (green) (**Fig. 3G,H**). There is also significant unwinding and displacement of the
307 C-terminal helices.

308 It is important to note that the images (**Fig. 3**) represent snapshots of individual
309 simulations at specific time points and do not capture the complete flexibility of the
310 terminal helices. Although the simulations of the large r-HDL-100 and r-HDL-120
311 particles show that the C-termini remain associated with the lipid surface, they could
312 detach in the presence of a protein such as ABCA1. Thus, these images represent low
313 energy states but not the sole states achievable by these systems.²⁸ It is also worth
314 noting that the time scale, potential energy functions, and restraints employed in the all-
315 atom and coarse-grained simulations tend to maintain the helical structure of the protein
316 residues.

317 **Clinical characteristics of LCAT-deficient and control subjects.**

318 Like the reconstituted HDL particles used in our model system studies, the extra-small
319 and small HDL particles in LCAT-deficient subjects are discoidal and composed largely
320 of APOA1, free cholesterol, and phospholipid.^{39,40} We therefore used serum HDL and
321 HDLs isolated from control and LCAT-deficient subjects to investigate the relevance of
322 our model system studies to human HDL.

323 We studied three groups of subjects: 14 controls, 6 subjects with heterozygous LCAT
324 deficiency (LCAT+/-), and 6 with LCAT deficiency (LCAT-/-).³¹ Two of the LCAT-/-
325 subjects were unrelated to the subjects in the family study. The three groups had similar
326 ages, percentages of females, and plasma LDL-C levels (**Table 1**). Compared to the
327 LCAT+/+ subjects, the LCAT+/- subjects had significantly lower plasma HDL-C levels,
328 as did the LCAT-/- subjects ($P=0.0005$). Plasma triglyceride levels were not significantly
329 different between the groups ($P=0.28$; Mixed effect model and Tukey-Kramer post-
330 tests). LCAT activity was undetectable in the LCAT-/- subjects (0 nmol/mL per h), with
331 significantly higher levels in the LCAT+/- subjects and LCAT+/+ subjects ($P<0.0001$).

332 **Extra-small HDL (XS-HDL) and small HDL (S-HDL) particles are enriched in LCAT-** 333 **deficient subjects.**

334 We used calibrated IMA to quantify total HDL (Total HDL) and four sizes of HDL
335 particles: extra-small HDL (XS-HDL), small HDL (S-HDL), medium HDL (M-HDL), and
336 large HDL (L-HDL) (**Fig. 4A; Supplemental Material, Table S3**). This method for
337 quantifying HDL-P yields a stoichiometry of APOA1 and sizes and relative abundances
338 of HDL subspecies that agree well with those determined by non-denaturing gradient
339 gel electrophoresis and analytical ultracentrifugation.^{23,41} In the LCAT+/+ subjects, M-
340 HDL (mean diameter, 9.2 ± 0.1 nm) was the most abundant particle population; it
341 accounted for ~50% of total HDL (**Fig. 4A**). All four sizes of HDL were detected in all the
342 control subjects. In contrast, subjects with partial LCAT deficiency had elevated levels of

343 XS-HDL (mean diameter, 7.8 ± 0.1 nm) and S-HDL (mean diameter, 8.4 ± 0.1 nm
344 diameter) particles (**Fig. 4A**). Subjects with complete LCAT deficiency exhibited only
345 XS-HDL (**Fig. 4A**).

346 The total concentration of HDL particles and the distribution of the different sizes of HDL
347 also differed significantly among the three groups (**Fig. 4B-F; Supplemental Material,**
348 **Table S3**). Mean Total-HDL-P levels in control subjects were 5.1 times higher than
349 those in LCAT^{-/-} subjects and 1.8 times higher than those in LCAT^{+/-} subjects
350 ($P < 0.0001$). This reflected significantly lower levels of both M-HDL and L-HDL in
351 subjects with complete or partial LCAT deficiency ($P < 0.0001$ for both M-HDL and L-
352 HDL). In contrast, mean levels of XS-HDL were higher in both LCAT^{-/-} and LCAT^{+/-}-
353 subjects than in control subjects. LCAT^{-/-} and LCAT^{+/-} subjects had similar levels of
354 XS-HDL and L-HDL.

355 **Serum HDL from LCAT-deficient subjects has normal macrophage and ABCA1** 356 **cholesterol efflux capacity despite low total HDL-P.**

357 We used serum HDL (APOB-depleted serum) to quantify the subjects' CEC, as
358 described by Rothblat et al.^{10,11} Macrophage and ABCA1 CEC were evaluated using
359 J774 macrophages stimulated with cAMP or BHK cells with mifepristone-inducible
360 expression of human ABCA1. CEC, quantified as the difference in cholesterol efflux with
361 and without induction of ABCA1, was a linear function of serum HDL concentration and
362 incubation time. A mixed effect model demonstrated that macrophage CEC and ABCA1
363 CEC did not differ significantly between LCAT^{-/-} and control subjects ($P > 0.3$).

364 To begin to identify the HDL subpopulations that drive macrophage CEC and ABCA1
365 CEC, we correlated the CEC of serum HDL with the particle concentration of each HDL
366 subpopulation from all the study subjects (**Supplemental Fig. S3**). Macrophage CEC
367 only correlated positively and strongly with the concentration of XS-HDL particle
368 concentration ($r = 0.55$, $P = 0.004$). These observations suggest that XS-HDL is an
369 important driver of cellular cholesterol export from both macrophages and through the
370 ABCA1 pathway.

371 **Small and extra-small HDL particles are the major promoters of macrophage CEC** 372 **and ABCA1 CEC in both LCAT-deficient subjects and control subjects.**

373 To further investigate how XS-HDL promotes CEC, we used ultracentrifugation and
374 high-resolution size exclusion chromatography to isolate XS-HDL from LCAT^{-/-}-
375 subjects. We then compared the CEC activity of XS-HDL with that of four sizes of HDL
376 isolated from LCAT^{+/+} subjects. The mean diameters of the isolated HDLs were 8.4
377 nm, 8.8 nm, 9.2 nm, and 14 nm (**Fig. 5A**; size distributions), respectively.

378 We quantified macrophage and ABCA1 CEC as described above for serum HDL.
379 Importantly, we incubated the cells with equimolar concentrations of isolated particles of
380 each size of HDL. CEC was a linear function of HDL particle concentration and the
381 incubation time used in the assays. XS-HDL isolated from LCAT^{-/-} subjects, composed
382 almost exclusively of 7.8 nm diameter particles (XS-HDL-sized), strongly promoted both
383 macrophage and ABCA1 CEC. However, it was less potent than 8.4 nm XS-HDL
384 particles isolated from LCAT^{+/+} subjects (**Fig. 5B**), which were composed of
385 approximately equimolar amounts of XS-HDL and S-HDL (as determined by calibrated

386 IMA). On a molar basis, 8.4 nm HDL isolated from control subjects was as effective as
387 lipid-free APOA1 in promoting both macrophage CEC and ABCA1 CEC. On a molar
388 basis, XS-HDL isolated from LCAT^{-/-} subjects promoted macrophage CEC much more
389 effectively than 8.8 nm HDL, 9.2 nm HDL, or 14 nm HDL isolated from control subjects,
390 and the differences were significant ($P=0.0002$ for 8.8 nm HDL, $P<0.0001$ for 9.2 nm
391 HDL, and $P<0.0001$ for 14 nm HDL). We obtained similar results when we determined
392 how effectively the different sizes of isolated HDL promoted ABCA1 CEC (**Fig. 5C**).

393 **LCAT converts small HDLs into large HDLs, markedly reducing CEC.**

394 To test the hypothesis that LCAT is one important factor controlling the CEC of
395 circulating HDL, we incubated control plasma and LCAT-deficient plasma with or
396 without recombinant human LCAT at 37°C for 2 h, stopped the LCAT reaction with
397 DTNB, and quantified ABCA1 CEC and HDL-P, using calibrated IMA. Control
398 experiments demonstrated that DTNB had no impact on quantification of ABCA1 CEC.

399 Before incubation with LCAT, the major HDL species in the LCAT^{-/-} subjects was XS-
400 HDL. In contrast, all 4 sizes of HDL were observed in the control subjects; M-HDL was
401 the most abundant species. LCAT treatment decreased the ABCA1 CEC of both control
402 plasma and LCAT^{-/-} plasma by ~50% (**Fig. 6A**). LCAT converted virtually all XS-HDL
403 and most S-HDL particles into larger HDLs in plasma of both control and LCAT-deficient
404 subjects (**Fig. 6B**). In plasma treated with LCAT, free cholesterol markedly decreased
405 while total cholesterol did not change significantly (**Fig 6C-D**).

406 Collectively, these observations support the proposal that small HDLs are the major
407 HDL species promoting both ABCA1 and macrophage CEC.

408

408 **Discussion**

409 To investigate the mechanisms that regulate HDL's ability to promote cholesterol efflux
410 by the ABCA1 pathway, we quantified the CEC of four different sizes of r-HDLs. As with
411 human HDL,^{7,8} the smallest r-HDL particles were the strongest promoters of cholesterol
412 efflux. Chemical crosslinking followed by MS/MS analysis showed that twice as many
413 intramolecular crosslinked peptides had formed in the smallest r-HDL than in the three
414 larger sizes, indicating that APOA1 had markedly higher mobility. When we plotted the
415 positions of the chemically crosslinked peptides on an HDL contact map, virtually all the
416 peptides detected in the two largest r-HDL particles were consistent with molecular
417 dynamics simulations of the double belt model of APOA1. In this model, the helical
418 repeats of two APOA1 molecules assume an anti-parallel helical structure that forms a
419 bundle surrounding the edges of discoidal HDL. Because the helical bundle is
420 amphipathic and has high lipid affinity,⁴² these observations strongly suggest that most
421 of the APOA1 in the two largest HDL particles is bound to lipid and therefore would not
422 be accessible to ABCA1.

423 The two smallest HDL particles showed a different pattern of chemically crosslinked
424 peptides: the peptides of APOA1's central region were consistent with the double belt
425 model, but those at the C-terminus were not (i.e., the C-termini in the APOA1 dimer are
426 not in a helical bundle). Moreover, the smallest HDL had the largest number of
427 detectable chemically crosslinked peptides in the C-terminus of APOA1. Taken
428 together, these data indicate that the C-terminus of APOA1 in the small HDL particles

429 have enhanced conformational mobility, likely due to a loss of overall helicity. Because
430 lipid interaction is a major driver of helical formation in APOA1, it is conceivable that the
431 C-terminus is detached from the lipid surface in the two smallest r-HDLs as observed in
432 the MD simulations of those particles.

433 The C-terminus of APOA1 plays a critical role in promoting cholesterol export by
434 ABCA1.⁴²⁻⁴⁴ We envision two factors that drive its increased mobility and loss of helical
435 structure in small HDLs. First, crowding, as small HDL's limited surface area might not
436 accommodate all of APOA1's helices, preventing the C-termini of APOA1 from lying on
437 the particle's surface. Second, extreme surface curvature, which could prevent
438 APOA1's C-terminal domain from fully interacting with lipid because it cannot turn
439 sharply enough to lie down on the surface. In this model, the two antiparallel C-termini
440 are "flipped" off the surface of smaller HDLs (**Fig. 7**), where their increased mobility and
441 freedom from lipid binding promote their engagement with ABCA1. In contrast, the C-
442 termini of larger HDLs are strongly bound to lipid and unable to interact productively
443 with ABCA1. On a molar basis, the smallest r-HDL and human HDL particles were as
444 efficient at promoting cholesterol efflux by the ABCA1 pathway as was lipid-free
445 APOA1, which is consistent with this model.

446 We suggest that the smaller, less lipidated HDL particles may not be fully "filled" with
447 lipid and remain effective substrates for ABCA1. At some point between diameters of 80
448 and 90 Å, the APOA1 C-terminus finds room to associate with the surface of the
449 particle, shutting down additional lipid accumulation by ABCA1 and possibly promoting
450 the release of a more 'mature' particle. In this scheme, the APOA1 C-terminus functions
451 as a lipid level switch that defines the maximal size of HDL particles formed by ABCA1.

452 An alternative hypothesis for the role of the C-terminus of APOA1 in promoting CEC is
453 that it involves binding of the protein to phospholipid-rich domains in the plasma
454 membrane of cells,^{45,46} which in turn promotes phospholipid and cholesterol efflux.
455 Consistent with this, deletion of helices H8-H10 decreases binding to lipid vesicles but
456 has little impact on cross-linking of radiolabeled APOA1 to ABCA1 on cells. However,
457 our recent studies⁴⁷ suggest that the lipid-affinity of APOA1 plays a role in promoting the
458 movement of phospholipids from the outer-leaflet of the plasma membrane into a
459 hydrophobic tunnel in the interior of the extracellular domain of ABCA1.

460 To test the relevance of our model system studies to human HDL, we used serum HDL
461 and HDL isolated from LCAT-deficient carriers. Like r-HDLs, the latter is discoidal and
462 composed of APOA1, free cholesterol, and phospholipid. We found that total HDL
463 particle concentration was markedly lower in subjects who completely lacked LCAT
464 activity. The major HDL subspecies in those subjects was XS-HDL, which is very similar
465 in size (78 Å in diameter) to the smallest r-HDL-80 particles used in our model system
466 studies (80 Å). In subjects who were only partially LCAT-deficient, the major HDL
467 subspecies were XS-HDL and S-HDL. In subjects with normal LCAT activity, we
468 detected all four sizes of HDL; M-HDL was the major species. Even though serum from
469 the LCAT-deficient subjects had very low HDL particle concentrations, ABCA1 CEC and
470 macrophage CEC were similar to that of the controls, strongly suggesting that the
471 ABCA1-specific activities of extra-small and small HDL were greater than those of the
472 larger HDL particles. Consistent with this proposal, macrophage and ABCA1 CEC
473 strongly and positively correlated with the concentration of XS-HDL in plasma.

474 To confirm these ideas, we used isolated HDL from subjects with and without complete
475 LCAT deficiency. Then we determined macrophage and ABCA1 CEC activity at equal
476 particle concentrations. The isolated particles had diameters of 8.4 nm, 8.8 nm, 9.2 nm,
477 and 14 nm—very similar to the sizes of XS-HDL, S-HDL, M-HDL, and L-HDL in plasma
478 as quantified by calibrated IMA. It is important to note that the isolated HDLs did not
479 precisely mimic the size distributions of the HDL subclasses in plasma from the LCAT-
480 deficient and control subjects. Extra-small HDL isolated from control subjects, which
481 was a mixture of XS-HDL and S-HDL, had the highest macrophage and ABCA1 CEC
482 specific activities; they were about 4–5-fold greater than those of the three larger sizes
483 of isolated HDL. XS-HDL isolated from the LCAT-deficient subjects did not contain S-
484 HDL and was less active than XS-HDL isolated from the control subjects; macrophage
485 CEC and ABCA1 CEC of the isolated HDLs were ~3-fold greater than for the larger
486 sizes of HDL. Lipid-free APOA1 was not detectable in the HDL used for these studies
487 because the particles were isolated by both ultracentrifugation and high-resolution size
488 exclusion chromatography.

489 These data suggest that both XS-HDL and S-HDL are the major contributors to
490 macrophage and ABCA1 CEC. This hypothesis is strongly supported by the
491 demonstration that incubating control plasma and LCAT-deficient plasma with LCAT
492 converted small HDLs into large HDLs and markedly diminished ABCA1 CEC. These
493 observations are remarkably concordant with animal studies, which demonstrated that
494 ABCA1 CEC of plasma HDL was increased in LCAT^{-/-} and LCAT^{+/-} mice.¹⁶ Moreover,
495 over-expression of LCAT significantly reduced macrophage cholesterol efflux by
496 plasma. Taken together, these observations suggest that XS-HDL and S-HDL, which
497 typically represent 20%-30% of total HDL, are key mediators of ABCA1 CEC and
498 perhaps cardioprotection.

499 CSL-112, a reconstituted HDL particle that promotes the formation of small and lipid-
500 poor APOA1 particles,^{18,19} is being tested in a large, randomized study to determine if it
501 reduces the risk of CVD events in post-MI patients. The demonstration that CSL-112
502 lowers incident CVD would strongly support the proposal that small HDLs are critical in
503 cardioprotection in humans.

504 Our demonstration that small and extra-small HDL particles potently promote
505 cholesterol efflux from macrophages raises the possibility that increased LCAT activity,
506 which converts smaller HDL particles into larger, cholesteryl ester-rich particles, is a risk
507 factor for atherosclerosis.⁴⁸ Consistent with this suggestion, overexpression of LCAT in
508 mice failed to increase reverse cholesterol transport from macrophages to bile.¹⁶ Serum
509 HDL from mice that overexpressed LCAT were less able to promote cholesterol efflux
510 from macrophages by the ABCA1 pathway than control mice.¹⁶ However, studies of the
511 relationships of LCAT to CVD risk in humans have yielded mixed results.^{49,50}

512 One limitation of our investigations is the small number of subjects in our study of LCAT
513 deficiency. However, the large differences in the concentrations of the various sizes of
514 HDL in the different groups of subjects and the consistency of the results with serum
515 HDL and isolated HDL strongly support the proposal that XS-HDL and S-HDL promote
516 cholesterol efflux from macrophages by the ABCA1 pathway. Another limitation is that
517 the size distributions of the isolated HDLs overlapped to some degree, reflecting the
518 limited resolution of size-exclusion chromatography. Nonetheless, the mean sizes of the

519 isolated HDLs were well separated, and the particle distributions were clearly distinct
520 from one another.

521 In summary, both our experiments and molecular dynamics simulations support the
522 proposal that small HDL particles are potent ligands for promoting cholesterol efflux
523 from macrophages by the ABCA1 pathway. In future studies, it will clearly be important
524 to determine whether XS-HDL and S-HDL predict CVD risk in humans, if LCAT mass
525 and/or activity associate with HDL size, and if risk prediction is independent of HDL-C.

526
527

528 **Acknowledgments.** We thank Dr. Priska von Haller and the Proteomics Resource
529 (UWPR95794, University of Washington) for technical support and Dr. Fabrizio Veglia
530 for statistical advice. Molecular dynamics simulations were performed at the National
531 Institutes of Health (NIH), Bethesda, MD (BIOWULF and Lobos clusters) and on the
532 Anton2 supercomputer. Access to Anton 2 was generously provided by D.E. Shaw
533 Research.

534

535 **Data availability.** The authors confirm that the data supporting the findings of this study
536 are available within the article and/or its supplementary materials.

537

538 **Sources of Funding.** This work was supported by awards from the NIH: T32HL007828,
539 R01HL149685, R35HL150754, P01HL151328, P01HL128203, P30DK017047,
540 R01HL153118, R01HL155601, R01HL144558, and R01HL149685; the American Heart
541 Association (15POST22700033); and the Intramural Program of the National Heart
542 Lung and Blood Institute of the NIH. Anton 2 time was provided by the Pittsburgh
543 Supercomputing Center (NIH R01GM116961).

544

545 **Disclosures.** K.E.B. serves on the Scientific Advisory Board of Esperion Therapeutics.

546

547

References

- 548 1. Gordon DJ and Rifkind BM. High-density lipoprotein--the clinical implications of
549 recent studies. *N Engl J Med.* 1989;321:1311-6.
- 550 2. Rader DJ and Hovingh GK. HDL and cardiovascular disease. *Lancet.*
551 2014;384:618-625.
- 552 3. Rader DJ and Tall AR. The not-so-simple HDL story: Is it time to revise the HDL
553 cholesterol hypothesis? *Nat Med.* 2012;18:1344-6.
- 554 4. Heinecke J. HDL and cardiovascular-disease risk--time for a new approach? *N*
555 *Engl J Med.* 2011;364:170-1.
- 556 5. Rader DJ, Alexander ET, Weibel GL, Billheimer J and Rothblat GH. The role of
557 reverse cholesterol transport in animals and humans and relationship to atherosclerosis.
558 *J Lipid Res.* 2009;50 Suppl:S189-94.
- 559 6. Oram JF and Heinecke JW. ATP-binding cassette transporter A1: a cell
560 cholesterol exporter that protects against cardiovascular disease. *Physiol Rev.*
561 2005;85:1343-72.

- 562 7. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK,
563 Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L and
564 Jessup W. HDL particle size is a critical determinant of ABCA1-mediated macrophage
565 cellular cholesterol export. *Circ Res*. 2015;116:1133-42.
- 566 8. He Y, Ronsein GE, Tang C, Jarvik GP, Davidson WS, Kothari V, Song HD,
567 Segrest JP, Bornfeldt KE and Heinecke JW. Diabetes Impairs Cellular Cholesterol
568 Efflux From ABCA1 to Small HDL Particles. *Circ Res*. 2020;127:1198-1210.
- 569 9. Yvan-Charvet L, Wang N and Tall AR. Role of HDL, ABCA1, and ABCG1
570 transporters in cholesterol efflux and immune responses. *Arteriosclerosis, thrombosis,
571 and vascular biology*. 2010;30:139-43.
- 572 10. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ and
573 Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum
574 specimens with similar high-density lipoprotein cholesterol to remove cholesterol from
575 macrophages. *Arterioscler Thromb Vasc Biol*. 2010;30:796-801.
- 576 11. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K,
577 French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH and
578 Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and
579 atherosclerosis. *N Engl J Med*. 2011;364:127-35.
- 580 12. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ,
581 Yuhanna IS, Rader DR, de Lemos JA and Shaul PW. HDL cholesterol efflux capacity
582 and incident cardiovascular events. *N Engl J Med*. 2014;371:2383-93.
- 583 13. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D,
584 Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT,
585 Wareham N and Rader DJ. Association of HDL cholesterol efflux capacity with incident
586 coronary heart disease events: a prospective case-control study. *Lancet Diabetes
587 Endocrinol*. 2015;3:507-13.
- 588 14. Kunnen S and Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe
589 in atherosclerosis? *Journal of Lipid Research*. 2012;53:1783-1799.
- 590 15. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen
591 B, Hoyt RF, Jr., Marcovina S, Brewer HB, Jr. and Santamarina-Fojo S. High plasma
592 HDL concentrations associated with enhanced atherosclerosis in transgenic mice
593 overexpressing lecithin-cholesteryl acyltransferase. *Nat Med*. 1997;3:744-9.
- 594 16. Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH and Rader
595 DJ. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage
596 reverse cholesterol transport in vivo. *Circulation*. 2009;120:160-9.
- 597 17. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C,
598 Frigerio B, Amato M, Sirtori CR, Alessandrini P, Arca M, Boscutti G, Cattin L, Gesualdo
599 L, Sampietro T, Vaudo G, Veglia F, Calandra S and Franceschini G. Functional lecithin:
600 cholesterol acyltransferase is not required for efficient atheroprotection in humans.
601 *Circulation*. 2009;120:628-35.
- 602 18. Kingwell BA, Nicholls SJ, Velkoska E, Didichenko SA, Duffy D, Korjian S and
603 Gibson CM. Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol
604 Efflux Capacity. *J Am Heart Assoc*. 2022;11:e024754.
- 605 19. Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO,
606 Therond P, Chapman MJ, Kontush A and Wright SD. Enhanced HDL Functionality in
607 Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL,

- 608 CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity. *Circ*
609 *Res.* 2016;119:751-63.
- 610 20. He Y, Song HD, Anantharamaiah GM, Palgunachari MN, Bornfeldt KE, Segrest
611 JP and Heinecke JW. Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in
612 Human High-density Lipoprotein. *Mol Cell Proteomics.* 2019;18:854-864.
- 613 21. Tubb MR, Smith LE and Davidson WS. Purification of recombinant
614 apolipoproteins A-I and A-IV and efficient affinity tag cleavage by tobacco etch virus
615 protease. *J Lipid Res.* 2009;50:1497-504.
- 616 22. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW and Oda MN. The
617 interplay between size, morphology, stability, and functionality of high-density
618 lipoprotein subclasses. *Biochemistry.* 2008;47:4770-9.
- 619 23. Hutchins PM, Ronsein GE, Monette JS, Pamir N, Wimberger J, He Y,
620 Anantharamaiah GM, Kim DS, Ranchalis JE, Jarvik GP, Vaisar T and Heinecke JW.
621 Quantification of HDL particle concentration by calibrated ion mobility analysis. *Clin*
622 *Chem.* 2014;60:1393-401.
- 623 24. Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, Reitz RE and
624 Krauss RM. Direct determination of lipoprotein particle sizes and concentrations by ion
625 mobility analysis. *Clin Chem.* 2008;54:1307-16.
- 626 25. Guha S, Li M, Tarlov MJ and Zachariah MR. Electrospray-differential mobility
627 analysis of bionanoparticles. *Trends Biotechnol.* 2012;30:291-300.
- 628 26. Rinner O, Seebacher J, Walzthoeni T, Mueller LN, Beck M, Schmidt A, Mueller M
629 and Aebersold R. Identification of cross-linked peptides from large sequence databases.
630 *Nat Methods.* 2008;5:315-8.
- 631 27. Pourmousa M, Song HD, He Y, Heinecke JW, Segrest JP and Pastor RW.
632 Tertiary structure of apolipoprotein A-I in nascent high-density lipoproteins. *Proc Natl*
633 *Acad Sci U S A.* 2018;115:5163-5168.
- 634 28. Pan AC, Weinreich TM, Piana S and Shaw DE. Demonstrating an Order-of-
635 Magnitude Sampling Enhancement in Molecular Dynamics Simulations of Complex
636 Protein Systems. *Journal of Chemical Theory and Computation.* 2016;12:1360-1367.
- 637 29. Jo S, Kim T, Iyer VG and Im W. CHARMM-GUI: a web-based graphical user
638 interface for CHARMM. *J Comput Chem.* 2008;29:1859-65.
- 639 30. Jones MK, Gu F, Catta A, Li L and Segrest JP. "Sticky" and "promiscuous", the
640 yin and yang of apolipoprotein A-I termini in discoidal high-density lipoproteins: a
641 combined computational-experimental approach. *Biochemistry.* 2011;50:2249-63.
- 642 31. Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, Arca M,
643 Bon GB, Boscutti G, Busnach G, Frasca G, Gesualdo L, Gigante M, Lupattelli G,
644 Montali A, Pizzolitto S, Rabbone I, Roller M, Ruotolo G, Sampietro T, Sessa A, Vaudo
645 G, Cantafora A, Veglia F, Calandra S, Bertolini S and Franceschini G. The molecular
646 basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive
647 study of molecular and biochemical findings in 13 unrelated Italian families. *Arterioscler*
648 *Thromb Vasc Biol.* 2005;25:1972-8.
- 649 32. George RT, Abuhatzira L, Stoughton SM, Karathanasis SK, She D, Jin C, Buss
650 N, Bakker-Arkema R, Ongstad EL, Koren M and Hirshberg B. MEDI6012: Recombinant
651 Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density
652 Lipoprotein Receptor-Mediated Reverse Cholesterol Transport. *J Am Heart Assoc.*
653 2021;10:e014572.

- 654 33. Mendez AJ, Oram JF and Bierman EL. Protein kinase C as a mediator of high
655 density lipoprotein receptor-dependent efflux of intracellular cholesterol. *J Biol Chem.*
656 1991;266:10104-11.
- 657 34. Segrest JP, Jones MK, Klom AE, Sheldahl CJ, Hellinger M, De Loof H and
658 Harvey SC. A detailed molecular belt model for apolipoprotein A-I in discoidal high
659 density lipoprotein. *J Biol Chem.* 1999;274:31755-8.
- 660 35. Mei X and Atkinson D. Crystal structure of C-terminal truncated apolipoprotein A-
661 I reveals the assembly of high density lipoprotein (HDL) by dimerization. *J Biol Chem.*
662 2011;286:38570-82.
- 663 36. Davidson WS and Thompson TB. The Structure of Apolipoprotein A-I in High
664 Density Lipoproteins. *J Biol Chem.* 2007;282:22249-22253.
- 665 37. Thomas MJ, Bhat S and Sorci-Thomas MG. Three-dimensional models of HDL
666 apoA-I: implications for its assembly and function. *J Lipid Res.* 2008;49:1875-83.
- 667 38. Lima DB, Melchior JT, Morris J, Barbosa VC, Chamot-Rooke J, Fioramonte M,
668 Souza T, Fischer JSG, Gozzo FC, Carvalho PC and Davidson WS. Characterization of
669 homodimer interfaces with cross-linking mass spectrometry and isotopically labeled
670 proteins. *Nat Protoc.* 2018;13:431-458.
- 671 39. Forte T, Norum KR, Glomset JA and Nichols AV. Plasma lipoproteins in familial
672 lecithin: cholesterol acyltransferase deficiency: structure of low and high density
673 lipoproteins as revealed by electron microscopy. *J Clin Invest.* 1971;50:1141-8.
- 674 40. Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G
675 and Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency
676 states. *J Lipid Res.* 2007;48:592-9.
- 677 41. Rosenson RS, Brewer HB, Jr., Chapman MJ, Fazio S, Hussain MM, Kontush A,
678 Krauss RM, Otvos JD, Remaley AT and Schaefer EJ. HDL measures, particle
679 heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular
680 events. *Clin Chem.* 2011;57:392-410.
- 681 42. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV and
682 Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a
683 review of secondary structure and function. *J Lipid Res.* 1992;33:141-66.
- 684 43. Shao B, Fu X, McDonald TO, Green PS, Uchida K, O'Brien KD, Oram JF and
685 Heinecke JW. Acrolein impairs ATP binding cassette transporter A1-dependent
686 cholesterol export from cells through site-specific modification of apolipoprotein A-I. *J*
687 *Biol Chem.* 2005;280:36386-96.
- 688 44. Mei X, Liu M, Herscovitz H and Atkinson D. Probing the C-terminal domain of
689 lipid-free apoA-I demonstrates the vital role of the H10B sequence repeat in HDL
690 formation. *J Lipid Res.* 2016;57:1507-17.
- 691 45. Vedhachalam C, Ghering AB, Davidson WS, Lund-Katz S, Rothblat GH and
692 Phillips MC. ABCA1-induced cell surface binding sites for ApoA-I. *Arterioscler Thromb*
693 *Vasc Biol.* 2007;27:1603-9.
- 694 46. Phillips MC. Is ABCA1 a lipid transfer protein? *J Lipid Res.* 2018;59:749-763.
- 695 47. Segrest JP, Tang C, Song HD, Jones MK, Davidson WS, Aller SG and Heinecke
696 JW. ABCA1 is an extracellular phospholipid translocase. *Nat Commun.* 2022;13:4812.
- 697 48. Heinecke JW. Small HDL promotes cholesterol efflux by the ABCA1 pathway in
698 macrophages: implications for therapies targeted to HDL. *Circ Res.* 2015;116:1101-3.

- 699 49. Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN,
700 Wareham NJ, Kastelein JJ, Khaw KT and Boekholdt SM. Plasma levels of
701 lecithin:cholesterol acyltransferase and risk of future coronary artery disease in
702 apparently healthy men and women: a prospective case-control analysis nested in the
703 EPIC-Norfolk population study. *J Lipid Res.* 2010;51:416-21.
- 704 50. Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ and Group PS.
705 High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence
706 of cardiovascular events: possible attenuation of cardioprotection associated with high
707 HDL cholesterol. *Atherosclerosis.* 2010;208:537-42.
708
709


710
711

Table 1. Clinical characteristics of the subjects in the family study.

Characteristic	Controls (LCAT+/+) n=14	Heterozygotes (LCAT+/-) n=6	Homozygotes (LCAT-/-) n=4	P-value
Age (years)	49±20	54±16	47±18	0.81
Female/Male (n)	5/9	2/4	4/2	---
HDL-C (mg/dl)	71±9	40±11	9.2±6.1	.0005
LDL-C (mg/dl)	114±32	109±34	111±74	0.22
Triglycerides (mg/dl)	111±61	121±30	253±130	0.28
LCAT activity (nmol/mL per h)	42±9	20±13	0±0	<.0001


712
713
714

P-values are from a mixed effect model and Tukey-Kramer post-tests.



715 **Figure 1. Calibrated IMA (A) and CEC (B) of reconstituted HDLs (r-HDLs) prepared**
716 **by cholate dialysis and fractionation by high-resolution size exclusion**
717 **chromatography.** (A) Representative IMA profiles of each size of r-HDL. To facilitate
718 comparison of the size distributions of the particles, the height of each r-HDL was set to
719 100%. The median sizes of the isolated particles were 8.0 ± 0.2 nm, 8.8 ± 0.1 nm, 9.6 ± 0.1
720 nm, and 12.2 ± 0.1 nm. (B) ABCA1-mediated cholesterol efflux capacity (CEC) using
721 equimolar concentrations of each size of r-HDL. Macrophage CEC and ABCA1 CEC of
722 serum HDL were quantified after a 4-h incubation with [³H]cholesterol-labeled J774
723 macrophages and BHK cells, without or with induction of ABCA1 expression with cAMP
724 and mifepristone, respectively. Cholesterol efflux was calculated as the percentage of
725 radiolabel in the medium of the cells divided by the total radioactivity of the medium and
726 cells. CEC was quantified as the difference in cholesterol efflux of cells with and without
727 induced expression of ABCA1. Results are representative of 5 independent experiments
728 with replicate analyses. **** $P < 0.001$, one-way ANOVA with Tukey-Kramer post-tests.

729




730

731 **Figure 2. Contact maps of the intermolecular (Inter) and intramolecular (Intra)**
 732 **APOA1 crosslinks detected by MS/MS in different sizes of r-HDL.** *Red regions and*
 733 *green regions* indicate the allowable distance of intermolecular and intramolecular
 734 peptide contacts (15.1 Å), respectively, in a molecular dynamics simulation of the LL5/5
 735 double-belt model of APOA1.²⁷ Crosslinks (o) between APOA1 residues are labeled.
 736 Semi-quantitative estimates of the strengths of interactions between residues were
 737 based on ion currents (**Supplemental Material, Table S2**), and they are indicated by
 738 the colors of the circles (green, strong; yellow, medium; red, weak). Note that we
 739 detected multiple intramolecular crosslinked peptides in the helix 8 to helix 10 region
 740 and helix 9 to helix 10 region of the C-terminus of APOA1 of r-HDL-80 and r-HDL-90
 741 particles, respectively, that are inconsistent with the classic double belt model. This
 742 indicates that the C-terminus of APOA1 has increased conformational freedom and
 743 does not assume the double belt conformation in that region. In contrast, the
 744 intramolecular crosslinked peptides detected in that region of the two largest sizes of
 745 HDL are consistent with the double belt model.

746


747

748



749


750 **Figure 3. Comparison of stepwise conformational changes in APOA1 between r-**
751 **HDL-120, r-HDL-100, r-HDL-90 and r-HDL-80 particles.** Cartoon representations:
752 **blue**, N-terminal 43 (residues 1-43); **green**, pairwise helix 5 (residues 121-143); **red**,
753 helix 10 (residues 220-243). **Red arrowheads** show the partially unfolded H7-H8
754 junctions. **Blue arrowheads** show the hairpin coil that allows helix 10 (**H10A** and **H10B**)
755 to fold onto the POPC headgroup surface. **A.** Top view of r-HDL-120. **B.** Side view of r-
756 HDL-120. **C.** Top view of r-HDL-100. **D.** Side view of r-HDL-100. **E.** Top view of r-HDL-
757 90. **F.** Side view of r-HDL-90. **G.** Top view of r-HDL-80. **H.** Side view of r-HDL-80. Note
758 that APOA1 in the two largest HDL particles (**A-D**; r-HDL-120 and -100) has a
759 conformation that is strongly lipid-associated and consistent with the classic double belt
760 model. In contrast, this structure is absent in both C-termini (**H10A,B**) of APOA1 in the
761 two smallest HDL particles (**E-H**; r-HDL-90 and -80).



762

763 **Figure 4. Quantification of total HDL and HDL subspecies in LCAT-deficient (-/-),**
 764 **LCAT-heterozygous (+/-), and control (+/+) subjects. (A)** Representative size and
 765 concentration profiles of HDL isolated from LCAT-deficient (-/-), LCAT-heterozygous
 766 (+/-), and control (LCAT +/+) subjects. **(B-F)** HDL isolated by ultracentrifugation from
 767 plasma (d=1.063-1.21 g/mL) was analyzed by calibrated IMA. The mean HDL
 768 subspecies sizes were: extra-small HDL (XS-HDL) 7.8 nm; small HDL (S-HDL) 8.4 nm;
 769 medium HDL (M-HDL) 9.2 nm; large HDL (L-HDL) 10.9 nm. Arb, arbitrary units. HDL
 770 isolated from plasma by ultracentrifugation was subjected to calibrated IMA. The sizes
 771 (mean, standard deviation) of the HDL subspecies were: extra-small HDL, 7.8±0.1 nm;
 772 small HDL, 8.4±0.1 nm; medium HDL, 9.2±0.1 nm; large HDL, 10.9±0.2 nm. The
 773 number of subjects was: LCAT+/, n=14; LCAT+/-, n=6; LCAT-/-, n=6. *P*-value, one-
 774 way ANOVA with Tukey-Kramer post-tests. *** *P*<0.001, ** *P*<0.01, * *P*<0.05.


775




776 **Figure 5. Calibrated IMA (A) and CEC (B) of HDL isolated from plasma of LCAT-**
 777 **deficient (LCAT^{-/-}) and control (XS-HDL, S-HDL, M-HDL, L-HDL) subjects. (A)**
 778 **Representative IMA size profiles of isolated HDL. To facilitate comparison of the**
 779 **particles' size distributions, the height of each isolated HDL fraction was set to 100%.**
 780 **The diameters of the isolated HDLs of LCAT^{-/-} subjects and control subjects were:**
 781 **LCAT^{-/-}, 7.8±0.1 nm; XS-HDL, 8.1±0.2 nm; S-HDL, 8.8±0.1 nm; M-HDL, 9.8±0.2 nm; L-**
 782 **HDL, 11.1±0.2 nm. Note that isolated XS-HDL is composed of both XS-HDL and S-HDL**
 783 **particles. (B, C) ABCA1-mediated cholesterol efflux capacity (CEC) of HDL isolated**
 784 **from LCAT^{-/-} subjects and control subjects. Macrophage CEC and ABCA1 CEC of were**
 785 **quantified with [³H]cholesterol-labeled J774 macrophages and baby hamster kidney**
 786 **cells after a 4-h incubation. Expression of ABCA1 was induced with cAMP and**
 787 **mifepristone, respectively. Cholesterol efflux was calculated as the percentage of**
 788 **radiolabel in the medium of the cells divided by the total radioactivity of the medium and**
 789 **cells. CEC was quantified as the difference in cholesterol efflux of cells with and without**
 790 **induced expression of ABCA1. Isolated HDLs were included in the media of the cells at**
 791 **equal particle concentrations. CEC of HDLs was normalized to CEC of cells exposed to**

792 10 $\mu\text{g}/\text{mL}$ of APOA1. *P*-value: one-way ANOVA with Tukey-Kramer post-tests.
793 ****P*<0.001, ***P*<0.01, **P*<0.05.

794
795



796
797 **Figure 6. ABCA1 CEC (A), HDL particle size distribution (B), free cholesterol (C)**
798 **and total cholesterol (D) content of control and LCAT-deficient plasma incubated**
799 **with LCAT.** Control plasma (N=3) and LCAT- deficient plasma (N=3) were incubated
800 with and without recombinant human LCAT (rLCAT+ and rLCAT-; 50 $\mu\text{g}/\text{mL}$) for 1 h at
801 37°C. The LCAT reaction was stopped with 2 mM DTNB and cooling on ice. Control
802 studies demonstrated that DTNB did not alter the CEC of plasma. DTNB was omitted
803 from plasma used to quantify cholesterol levels because it interfered with the enzymatic
804 assay. ABCA1 CEC of plasma was quantified using [^3H]cholesterol-labeled BHK cells
805 as described in the legend to **Fig. 5**. *P*-values, ratio-t test.



806

807 **Figure 7. The “flipped ends” model for the increased ABCA1 activity of small**
808 **HDLs.** In large HDL particles, the C-termini of the APOA1 dimer are in antiparallel
809 helical bundles that are amphipathic and strongly associated with lipid. In small HDL
810 particles, the reduced surface area and high surface curvature force the C-termini off
811 the particles, increasing their mobility. The termini also are less lipid-associated
812 because APOA1 loses its amphipathic double belt structure. Decreased lipid
813 association and increased mobility of the C-termini (helices H8–10) promote the
814 engagement of APOA1 with the clasp domains of ABCA1, stimulating cholesterol
815 export from the cell. An alternative hypothesis is that the C-termini of APOA1

816 promote microsolvubilization of phospholipids and cholesterol from phospholipid-rich
817 domains in the plasma membrane of cells (see Discussion).
818